Related Experiment Video
Updated: Aug 18, 2026
Modeling Cataract Surgery in Mice
Published on: December 1, 2023
Preoperative injection of mitomycin C in combined pterygium and cataract surgery
Rahamim Avisar1, Shmuel Bar, Dov Weinberger
1Department of Ophthalmology and External Eye Disease Clinic, Rabin Medical Center, Petah Tiqva, Tel Aviv University, Israel. lavisar@bezeqint.net
Purpose:
To evaluate the safety and efficacy of a preoperative injection of mitomycin C (MMC) in combined pterygium and cataract surgery.
Methods:
This was a prospective, nonrandomized, interventional trial. Thirty-nine patients with cataract and pterygium enrolled in a prospective, nonrandomized trial. All patients underwent combined pterygium and cataract surgery. Twenty-seven received a single 0.1-mL injection of 0.15 mg/mL MMC into the pterygium head 4 weeks before surgery and 12 did not. Patients were followed for 12 to 23 months postoperatively. Recurrence of pterygium, side effects, and complications of MMC were recorded.
Results:
Recurrent pterygium developed in none of the patients treated with MMC preoperatively and in 5 of the nontreated patients. Two patients in the pretreated group had allergic conjunctivitis immediately after MMC injection. No other local eye complications or adverse systemic reactions were recorded.
Conclusions:
Preoperative injection of MMC into the head of the pterygium 4 weeks prior to combined pterygium and cataract surgery resulted in no recurrence and no serious complications up to 12 to 23 months of follow-up postoperatively. This procedure may be recommended to save time and cost and to prevent the possible side effects of MMC when administered topically at the time of cataract surgery. Further follow-up and additional studies will be needed to determine the long-term safety and efficacy.
